Arcturus Therapeutics (ARCT) News Today $17.30 +0.01 (+0.06%) Closing price 04:00 PM EasternExtended Trading$17.74 +0.44 (+2.54%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Arcturus Therapeutics to Attend Upcoming Investor ConferencesAugust 26 at 4:32 PM | mms.businesswire.comLeerink Partners Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $54.00August 24, 2025 | americanbankingnews.comArcturus Therapeutics price target lowered to $54 from $63 at LeerinkAugust 22, 2025 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.9% - Should You Sell?August 20, 2025 | marketbeat.comResearch Analysts Set Expectations for ARCT FY2025 EarningsAugust 16, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Estimate for ARCT EarningsAugust 16, 2025 | marketbeat.comQ3 EPS Estimate for Arcturus Therapeutics Lifted by AnalystAugust 16, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading 24.8% Higher - What's Next?August 15, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comWells Fargo & Company Has Lowered Expectations for Arcturus Therapeutics (NASDAQ:ARCT) Stock PriceAugust 13, 2025 | marketbeat.comWilliam Blair Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)August 12, 2025 | theglobeandmail.comScotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)August 12, 2025 | theglobeandmail.comArcturus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)August 12, 2025 | benzinga.comArcturus Therapeutics Shares Climb on Loss, Revenue Beating Analyst ExpectationsAugust 12, 2025 | marketwatch.comArcturus Therapeutics price target raised to $49 from $47 at CitiAugust 12, 2025 | msn.comArcturus Therapeutics price target lowered to $42 from $45 at Wells FargoAugust 12, 2025 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Posts Quarterly Earnings Results, Beats Expectations By $0.77 EPSAugust 12, 2025 | marketbeat.comArcturus Therapeutics shares edge higher despite earnings miss in Q2August 12, 2025 | uk.investing.comArcturus Therapeutics: Q2 Earnings SnapshotAugust 12, 2025 | sfgate.comArcturus outlines pivotal trial plans and advances CF and OTC programs with regulatory meetings expected in 2026August 12, 2025 | msn.comArcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline ProgressAugust 12, 2025 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call TranscriptAugust 11, 2025 | seekingalpha.comArcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Hold at Wall Street ZenAugust 10, 2025 | marketbeat.comWhat To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 EarningsAugust 9, 2025 | finance.yahoo.comHow RFK Jr.’s mRNA crackdown affects vaccine making and future pandemicsAugust 7, 2025 | yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Buy" by BrokeragesAugust 7, 2025 | marketbeat.comLipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034August 5, 2025 | finance.yahoo.comArcturus Therapeutics (ARCT) Expected to Announce Earnings on MondayAugust 4, 2025 | marketbeat.comY Intercept Hong Kong Ltd Takes Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)July 31, 2025 | marketbeat.comARK Investment Management LLC Raises Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)July 27, 2025 | marketbeat.comNikko Asset Management Americas Inc. Has $20.38 Million Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)July 27, 2025 | marketbeat.comArcturus Therapeutics to Attend Upcoming Investor ConferencesJuly 23, 2025 | businesswire.comArcturus Therapeutics Holdings Inc. Stock Grades - Barron'sJuly 16, 2025 | barrons.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by AnalystsJuly 13, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Downgraded by Wall Street Zen to "Sell"July 5, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (ARCT) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comSumitomo Mitsui Trust Group Inc. Lowers Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)July 4, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Price Target Raised to $35.00 at ScotiabankJuly 2, 2025 | marketbeat.comArcturus Therapeutics: High Hopes, High Hurdles For Its mRNA PipelineJuly 2, 2025 | seekingalpha.comArcturus Therapeutics stock rises on positive OTC deficiency trial dataJune 30, 2025 | za.investing.comArcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency TreatmentJune 30, 2025 | msn.comArcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency ProgramJune 30, 2025 | businesswire.comArcturus Therapeutics (NASDAQ:ARCT) Stock Crosses Below 200 Day Moving Average - Time to Sell?June 27, 2025 | marketbeat.comVerve Therapeutics (VERV) was downgraded to a Hold Rating at William BlairJune 18, 2025 | theglobeandmail.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Buy" by AnalystsJune 18, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank of America Corp DEJune 12, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 11, 2025 | marketbeat.comHow mRNA technology is offering a potential solution for patients with rare diseasesJune 10, 2025 | bbc.comBCantor Fitzgerald Weighs in on ARCT FY2026 EarningsJune 10, 2025 | marketbeat.comSquarepoint Ops LLC Sells 22,752 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)June 9, 2025 | marketbeat.com Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARCT Media Mentions By Week ARCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.511.02▲Average Medical News Sentiment ARCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼54▲ARCT Articles Average Week Get the Latest News and Ratings for ARCT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Arcturus Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Adaptive Biotechnologies News Sarepta Therapeutics News ANI Pharmaceuticals News Arcutis Biotherapeutics News Vericel News Dyne Therapeutics News Apogee Therapeutics News Twist Bioscience News Beam Therapeutics News Cidara Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access